Back to the main directory
EarningsReview / Equity
- by BNP Paribas Exane
- Q4 company contact feedback by BNP Paribas Exane
- Catching Up Ahead of C4Q24 Earnings by BNP Paribas Exane
- Results Flash - Q1 EBITDA in-line, FCF decent, Q2 downside risk by BNP Paribas Exane
- What to expect from Q3’FY25 results by BNP Paribas Exane
- What's the big deal? - December edition by BNP Paribas Exane
- Bonne Année by BNP Paribas Exane
- Quick take following small sell-side call by BNP Paribas Exane
- Protector (Buy, TP: NOK350.00) - Set for strong 2025e momentum by DnB Markets
- YIT (Sell, TP: EUR2.00) - Set for zero Q4 EPS by DnB Markets
- Sustainability Christmas Recap | 16 déc. 2024 – 6 jan. 2025 by Oddo BHF
- 2025: The bonds are aligning by BNP Paribas Exane
- Marking the names to market by BNP Paribas Exane
- 2025: Turning another new leaf, but little relief by BNP Paribas Exane
- Structural advantage by BNP Paribas Exane
- Running Ahead of the Pack (and the Headwinds). U/G to Outperform by BNP Paribas Exane
- For your eyes only by BNP Paribas Exane
- Q125 Revenue: slow start we see as more in line than a miss, but very demanding H225e still required to meet guidance by BNP Paribas Exane
- Interparfums - La succession se dessine. by MidCap Partners
- INVEST SECURITIES-TME PHARMA : Importante souscription des actionnaires - ACHAT, OC 0,17€ by Invest Securities
- INVEST SECURITIES-AUDACIA :Un pari devenu une réalité juste à temps - ACHAT, OC 9,6€ by Invest Securities
- Interparfums - The succession is taking shape. by MidCap Partners
- China Solar Glass by HSBC
- Solid Xmas, but implied slowdown amidst increasing inflation will likely temper expectations by BNP Paribas Exane
- Pressing the HEV Pedal by BNP Paribas Exane